Empirical Finance LLC Boosts Stock Position in Illumina, Inc. $ILMN

Empirical Finance LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 20.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,805 shares of the life sciences company’s stock after acquiring an additional 996 shares during the quarter. Empirical Finance LLC’s holdings in Illumina were worth $554,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rise Advisors LLC boosted its stake in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Parkside Financial Bank & Trust lifted its holdings in Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in Illumina in the 2nd quarter valued at about $41,000. NewSquare Capital LLC grew its stake in Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after acquiring an additional 558 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research reports. Canaccord Genuity Group boosted their price target on Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a report on Friday, October 31st. Daiwa America downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Robert W. Baird set a $109.00 price target on Illumina in a research note on Friday, October 31st. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a report on Tuesday, August 12th. Finally, Morgan Stanley increased their target price on shares of Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $115.00.

Illumina Trading Down 0.7%

Shares of NASDAQ ILMN opened at $119.26 on Friday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06. The business has a fifty day moving average price of $104.65 and a 200 day moving average price of $97.05. The stock has a market capitalization of $18.22 billion, a P/E ratio of 15.10, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm’s revenue was up .4% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.17% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.